Compare VFS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFS | PRAX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Vietnam | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 8.6B |
| IPO Year | N/A | 2020 |
| Metric | VFS | PRAX |
|---|---|---|
| Price | $3.21 | $303.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $5.83 | ★ $516.93 |
| AVG Volume (30 Days) | 284.5K | ★ 589.2K |
| Earning Date | 11-21-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,554,394,588.00 | $7,463,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $54.07 | $29,535.93 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 81.20 | ★ 364.98 |
| 52 Week Low | $2.56 | $26.70 |
| 52 Week High | $3.94 | $326.91 |
| Indicator | VFS | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 39.13 | 58.41 |
| Support Level | $3.20 | $288.57 |
| Resistance Level | $3.34 | $325.22 |
| Average True Range (ATR) | 0.08 | 17.04 |
| MACD | -0.02 | -2.41 |
| Stochastic Oscillator | 7.79 | 67.85 |
VinFast Auto Ltd manufactures cars, and motor vehicles, renders leasing activities, trades smartphones, and related businesses. The company is engaged in designing and manufacturing premium EVs, e-scooters, and e-buses. The company's initial EV product line is an all-new range of fully electric A- through E-segment SUVs. The Company has three reportable segments, namely Car, E-scooter and Ebus. The Car segment includes the design, development, manufacturing and sales of cars and related battery lease and battery charging services for cars. The E-scooter segment includes the design, development, manufacturing and sales of e-scooters and related battery lease and battery charging service for e-scooters. The Ebus segment includes the design, development, manufacturing and sales of Ebus.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.